ClinicalTrials.gg
RecruitingNCT07240441EPISODE_VTUpdated Nov 20, 2025

Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)

An interventional study of Endocardial VT ablation and Endo-epicardial VT ablation in Ventricular Tachycardias, Myocardial Infarction (MI) and Implantable Cardiac Defibrillator, sponsored by MEDICOVER SP Z O.O.. Recruiting at 9 sites in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by MEDICOVER SP Z O.O. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2025, registered Nov 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Tachycardia, Ventricular with a site in Poland — 5 open to participants now, 6 under way, none of them phase 3. Tachycardia, Ventricular · Poland.

Planned enrollment
10th of 15
220 · median 504
Started
2025
with 1 other
No phase
11 of 19
5 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
MEDICOVER SP Z O.O.

Among the 19 studies in Tachycardia, Ventricular with a site in Poland, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 18th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

5 of the 19 studies in Tachycardia, Ventricular with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Tachycardia, Ventricular with a site in Poland, or all of them as a file.
02

Study summary

The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria.

Read the detailed description

The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria. Nowadays, most often ablation is performed using only endocardial approach. The rate of VT recurrences after such ablation may exceed 50%, which is largely due to the inability to remove all arrhythmogenic substrate. At the same time, in cases where all potentially arrhythmogenic substrate is removed, the immediate and long-term results are better, both in terms of recurrence and prognosis. Single reports on endo-epicardial ablation as the first-line therapy in patients with post-infarction VT indicate a higher efficacy of this approach compared to endocardial ablation. Similar conclusions emerge from meta-analyses. This is probably due to a more complete removal of the arrhythmogenic substrate located mainly in the epicardium or intramurally.

In the endo-epicardial group pericardial sac puncture will be performed after filling it with carbon dioxide, which creates a space for safe puncture.

Ablation procedures will be performed as standard. The electrophysiological systems and ablation electrodes used in the study will be standard devices that research centers are equipped with. Their use will be in accordance with the procedures of the center and the instructions for use.

03

Conditions studied

  • Ventricular Tachycardias
  • Myocardial Infarction (MI)
  • Implantable Cardiac Defibrillator
  • Ablation

Keywords

  • ventricular tachycardia
  • myocardial infarction
  • epicardial access
  • pericardial sac puncture
  • ablation
  • implantable cardioverter defibrillator
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Status after myocardial infarction (minimum 3 months before inclusion in the study).
  • Documented post-infarction VT or VF.
  • Implantable ICD (at least 2 weeks before ablation) or CRT-D (at least 2 months before ablation).
  • A history of at least one from below:

    1. One or more high energy interventions.
    2. Three or more adequate antitachycardia pacing therapies, including one symptomatic.
    3. Three or more episodes of VT in 24 hours (interrupted by ATP or shock) - electrical storm.
    4. Sustained VT recorded on with a cycle length longer than the ICD detection threshold.
  • Age between 18 and 85 years.
  • Signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Obesity with > 40 kg/m2.
  • Left ventricle \< 20%.
  • Pregnancy or breastfeeding.
  • Renal failure ( \< 20 mL/min/1.73m2).
  • Fresh ballot thrombus in the left ventricle.
  • Suspicion of massive adhesions in the pericardium that may impede pericardial puncture.
  • Ablation of the post-infarction VT in the left ventricle in medical history.
  • Previous heart surgery.
  • Acute conditions that prevent ablation (including active infection, overt hyperthyroidism and others listed below).
  • Active neoplastic disease.
  • Heart failure with IV.
  • less than 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Active comparator
    Endocardial post MI VT ablation group

    Endocardial post MI VT radiofrequency ablation using contact force irrigated catheters, standard electrophysiological systems, electroanatomical mapping systems and RF generators.

    Procedure: Endocardial VT ablation

  • Experimental
    Endo-epicaridal post MI VT ablation group

    Endo-epicardial post-myocardial infarction VT radiofrequency ablation will be performed using contact force irrigated catheters, standard electrophysiological systems, electroanatomical mapping systems and RF generators. Access to the pericardial sac will be preceded by CO2 insufflation into its lumen.

    Procedure: Endo-epicardial VT ablation

Interventions

  • ProcedureEndocardial VT ablation

    Post-myocardial infarction VT radiofrequency ablation using a standard endocardial approach

  • ProcedureEndo-epicardial VT ablation

    Post-myocardial infarction VT radiofrequency ablation using an endo-epicardial approach with pericardial sac puncture preceded by CO2 insufflation

06

What researchers measure

Primary outcomes

  1. Death from any cause

    Death from any cause

    Time frame: 2 years

  2. Electrical storm (3 episodes of VT in 24 hours)

    Time frame: 2 years

  3. Adequate ICD shock during 24 months of follow-up.

    Time frame: 2 years

07

Study locations

2 of 9 sites recruiting
  • Medicover Hospital
    Warsaw, Masovian Voivodeship 02-972, Poland
    Recruiting
  • Medical University of Warsaw
    Warsaw, Masovian Voivodeship, Poland
    Recruiting
  • National Institute of Cardiology
    Warsaw, Masovian Voivodeship, Poland
    Not yet recruiting
  • University Hospital No. 1 in Bydgoszcz
    Bydgoszcz, Poland
    Not yet recruiting
    • Krupa W · Contact
  • University Clinical Center based in Gdańsk
    Gdansk, Poland
    Not yet recruiting
    • Królak T · Contact
  • Independent Public Health Care Facility University Hospital in Krakow
    Krakow, Poland
    Not yet recruiting
    • Jastrzębski M · Contact
  • University Clinical Hospital in Poznań
    Poznan, Poland
    Not yet recruiting
  • University Clinical Hospital No. 2 PUM in Szczecin
    Szczecin, Poland
    Not yet recruiting
    • Kiedrowicz R Radosław Kiedrowicz, MD, PhD · Contactradkied@wp.pl
  • Grochowski Hospital named after Dr. Rafał Masztak, MD
    Warsaw, Poland
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2030, 69 months after the start.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 69 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 20, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240441
Lead sponsor
MEDICOVER SP Z O.O.
Collaborators
National Institute of Cardiology, Warsaw, Poland, Medical University of Warsaw
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Feb 3, 2025
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Nov 20, 2025

Study contacts

Derejko P Prof. Paweł Derejko, MD, PhD
Contact
pawel.derejko@medicover.pl
+48 603338871
Fabijańska M Project Manager for Clinical Trials in Medicover Hospital
Contact
magdalena.fabijanska@medicover.pl
+48 519532444

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion